From domperidone to metopimazine: Anticipating the media impact of pharmacovigilance announcements

Therapie. 2021 Sep-Oct;76(5):500-501. doi: 10.1016/j.therap.2020.10.002. Epub 2020 Oct 23.

Authors

Michaël Rochoy¹, Camille Potey², Sophie Gautier², Johana Béné²

Affiliations

¹ University Lille, CHU Lille, ULR 2694 - METRICS, CERIM, General Medicine Department, 59000 Lille, France; Inserm, UMR-S1172, Center for Pharmacovigilance, CHU de Lille, University Lille, 59037 Lille, France. Electronic address: [email protected].
² Inserm, UMR-S1172, Center for Pharmacovigilance, CHU de Lille, University Lille, 59037 Lille, France.

PMID: 33190851
DOI: 10.1016/j.therap.2020.10.002

No abstract available

Keywords: Antiemetics; Domperidone; Media impact; Metopimazine; Pharmacovigilance.

Publication types

Letter

MeSH terms

Antiemetics*
Domperidone / adverse effects
Humans
Isonipecotic Acids*
Pharmacovigilance
Vomiting

Substances

Antiemetics
Isonipecotic Acids
metopimazine
Domperidone